Wir sind mit live! Mehr erfahren

AtriCure

ATRC

Börsenwert 2,85 Mrd. $

56,07 USD

-1,71

2,96 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

55,32

-0,75

1,34 %

1 Tag

-2,96 %

5 Tage

-0,39 %

1 Monat

-1,87 %

3 Monate

57,41 %

6 Monate

94,15 %

Seit Jahresbeginn

42,78 %

1 Jahr

50,56 %

5 Jahre

-21,27 %

10 Jahre

233,16 %

Profil: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Mitarbeiter: 1.350

Gesundheitswesen Medizinische Geräte und Verbrauchsmaterialien

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 35,3 %

Neutral 52,9 %

Negativ 11,8 %

AtriCure to Announce Third Quarter 2026 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2026 financial results on Tuesday, November 3, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, November 3, 2026, to discuss its third quarter financial results. Those interested in liste.

AtriCure to Announce Third Quarter 2026 Financial Results

Zacks Investment Research

Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

The Motley Fool

AtriCure CTO Sells 3,657 Shares

The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.

AtriCure CTO Sells 3,657 Shares

Zacks Investment Research

Do Options Traders Know Something About AtriCure Stock We Don't?

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

Do Options Traders Know Something About AtriCure Stock We Don't?

Zacks Investment Research

AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?

Zacks Investment Research

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may a.

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

AtriCure: Promising Cardiovascular Surgical Platform

AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.

AtriCure: Promising Cardiovascular Surgical Platform

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

The Motley Fool

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt